Advaxis, Inc. (ADXS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADXS POWR Grades
- Growth is the dimension where ADXS ranks best; there it ranks ahead of 95.13% of US stocks.
- The strongest trend for ADXS is in Momentum, which has been heading down over the past 186 days.
- ADXS ranks lowest in Stability; there it ranks in the 1st percentile.
ADXS Stock Summary
- ADXS has a higher market value than only 9.26% of US stocks; more precisely, its current market capitalization is $49,578,647.
- With a price/sales ratio of 26.58, Advaxis Inc has a higher such ratio than 92.48% of stocks in our set.
- Advaxis Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -28.87%, greater than the shareholder yield of just 9.1% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Advaxis Inc are OIIM, BMRA, KMDA, SEAC, and ALT.
- ADXS's SEC filings can be seen here. And to visit Advaxis Inc's official web site, go to www.advaxis.com.
ADXS Stock Price Chart Interactive Chart >
ADXS Price/Volume Stats
|Current price||$0.41||52-week high||$1.57|
|Prev. close||$0.42||52-week low||$0.26|
|Day high||$0.42||Avg. volume||11,022,259|
|50-day MA||$0.65||Dividend yield||N/A|
|200-day MA||$0.56||Market Cap||57.10M|
Advaxis, Inc. (ADXS) Company Bio
Advaxis Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology. The company was founded in 2002 and is based in Princeton, New Jersey.
ADXS Latest News Stream
|Loading, please wait...|
ADXS Latest Social Stream
View Full ADXS Social Stream
Latest ADXS News From Around the Web
Below are the latest news stories about Advaxis Inc that investors may wish to consider to help them evaluate ADXS as an investment opportunity.
PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021. Presentation Details: Title: A phase 1 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.Session Type: Poster SessionAbstract Number: 2616Date and Time: June 4, 2021, 9:00 AM (EDT) About Advaxis, Inc.Advaxis, Inc. is a clinical-stage biotechnology compan...
Advaxis, Inc. (NASDAQ: ADXS), CEO Ken Berlin presented at the Benzinga Biotech Small-Cap Conference on March 24, 2021. Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, is making new waves as it takes definitive steps to prove that the company is “no longer your grandfather’s Advaxis,” according to company CEO Ken Berlin. Among Advaxis’s new steps is an agreement with the Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer. The company has also announced new data relating to developing a novel flow immunophenotyping assay to accurately evaluate total PD-1 expression as a pharmacodynamic marker during PD-1 bloc...
Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of (i) 17,577,400 shares of common stock , (ii) 7,671,937 pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,671,937 shares of common stock and (iii) registered common share purchase warrants to purchase 11,244,135 shares of common stock. The Company has also agreed to issue to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase 14,005,202 shares of the Company’s common stock. Each share ...
Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting for both free and drug-bound PD-1 Results confirm on-mechanism activation of innate and adaptive immune responses in patients with demonstrated clinical benefit from ADXS-503 treatment in combination with pembrolizumab PRINCETON, N.J., April 10, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commer...
Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday. Viviane Mason, a biopharma industry veteran and investor, set the ball rolling with a session on what an investor should look for when investing in biotech stocks. Mason explained the long-winding drug approval process and the catalysts an investor needs to watch. Mason suggested looking for companies that have recently raised capital, as she said it's a signal a company has a cash runway. The following are biotech companies that investors heard from at the Benzinga conference. Presentations Lantern Pharma Inc. (NASDAQ: LTRN): Lantern CEO Panna Sharma recommends leveraging data — especially on similar classes of drugs in the market ...
ADXS Price Returns